retatrutide clinical data retatrutide is one of the most exciting medications currently being studied for obesity and metabolic disease-but there's one important thing to understand: It is NOT approved yet. I get asked almost daily, “ First Retatrutide phase 3 data,

Zepbound lists at roughly $1,000 to $1,300 monthly, with self-pay vials often $349 to $499

1 Ribeiro CB, et al

At Summit Pep Labs, we are committed to supplying researchers with premium-quality compounds manufactured to rigorous analytical standards

Retatrutide for type 2 diabetes: Phase 2 trial results (36-week study, HbA1c reductions, weight loss) New England Journal of Medicine (2023) Jastreboff AM, et al

GLP-3 is informal shorthand used in catalogs and some literature for triple agonists of the GLP-1, GIP, and glucagon receptors

In addition, we used an alternative protocol in new set of experiments where we studied (in the presence of cilostamide) the effect of retatrutide, ryanodine, and nifedipine or control on different muscle strips from the same patient head to head: we first gave cilostamide, then added 10 nM ryanodine, and then added retatrutide (Fig